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a b s t r a c t
We report a case of t(8;21) acute myeloid leukemia presenting as severe aplastic anemia. While initial
bone marrow biopsy lacked any cytogenetic abnormalities in 20 analyzed metaphases, repeat bone
marrow biopsy eight days later demonstrated this translocation. Initial cytogenetic analysis of 20
metaphases was therefore insufﬁcient to make the diagnosis of hypocellular acute myeloid leukemia. We
discuss that further complementary molecular tests, such as CGH, would likely provide a more robust
diagnosis of hematopoietic diseases.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Aplastic anemia (AA) is a rare disease characterized by pancy-
topenia and a hypocellular bone marrow. Speciﬁc cytogenetic
abnormalities, monosomy 7 and trisomy 8, are frequently asso-
ciated with clonal evolution [1]. Clonal cytogenetic abnormalities
also may be present with hypocellular bone marrow morphology:
some experts have used them to differentiate AA from hypoplastic
myelodysplastic syndrome (MDS) [2], while others accept certain
aberrations as consistent with AA [3]. Although cryptic RUNX1/
AML1 lesions have been reported in patients with Fanconi anemia
and MDS [4], the (8;21) translocation is not observed by standard
cytogenetic methods in bone marrow failure diseases.
2. Case report
A 23-year-old Ecuadorian homemaker, resident in the
United States, presented to medical attention with a peritonsillar
abscess. Laboratory studies at presentation showed white blood
cells 1.38 k/μL, absolute neutrophil count 0 k/μL, hemoglobin
7.4 g/dL, absolute reticulocyte count 5 k/μL, and platelets 38 k/μL.
Initial bone marrow biopsy revealed 5% cellularity with minimal
trilineage hematopoiesis. Cytogenetics showed normal female
karyotype 46,XX in all 20 analyzed metaphases. She was referred
to the National Institutes of Health (NIH) for evaluation and
consideration for immunosuppressive therapy (IST) and eltrombo-
pag on a clinical trial (NCT01623167). There was no evidence of an
inherited bone marrow failure disorder on physical examination or
from a detailed family history. Tests for Fanconi anemia (diepox-
ybutane stress) and telomere disorders (leukocyte telomere
length) were normal. Flow cytometric evaluation for paroxysmal
nocturnal hemoglobinuria (PNH) was negative. Repeat bone mar-
row analysis performed immediately prior to IST (as required by
protocol) demonstrated 10% cellularity, no dysplasia, nor increased
number of blasts. Less than 1% of cells were CD34 positive. Severity
of neutropenia (ANCo200/μL) prompted immediate treatment on
protocol, beginning with equine antithymocyte globulin (ATG) and
cyclosporine, standard for severe AA. However, two days after
completion of IST, standard cytogenetic analysis returned t(8;21)
(q22;q22) in 3 out of 20 metaphases, with conﬁrmation by FISH
(Fig. 1A). The patient was placed “off protocol” and did not receive
the study drug, eltrombopag. This signiﬁcant cytogenetic abnorm-
ality was unexpected and was inconsistent with the marrow
morphology. Three months after initial presentation at NIH,
conﬁrmatory bone marrow evaluation showed 2/2 metaphases
with t(8;21) abnormality. Focally increased CD34þ cells were
observed by IHC (Fig. 1B, C) but not by ﬂow cytometry. Her clinical
status was unchanged after receiving IST: she remained severely
pancytopenic and transfusion-dependent. Chemotherapy for AML
was withheld due to the severe pancytopenia, hypocellularity, and
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absence of increased blasts. Progression to frank leukemia with
circulating blasts did not occur until eight months following initial
presentation. She underwent allogeneic stem cell transplantation
from a matched sibling donor. She had minimal grade chronic
GVHD of the skin, that was successfully treated with steroids. Eight
months after successful bone marrow transplant, the patient is in
remission.
The core binding factor leukemia involving translocation
of 8;21 (q22;q22), generating a fusion of RUNX1 and AML1 genes,
is considered leukemia-deﬁning, regardless of the number of
blasts [5]. This unusual case prompted us to perform comparative
genomic hybridization (CGH). Single nucleotide polymorphism
(SNP) based CytoScan high-density microarray [6] was performed
on DNA derived from the patient's bone marrow cells. Sample
obtained at NIH at initial diagnosis had no identiﬁable gains or
losses of more than 100,000 bp. However, multiple, large regions
of copy neutral loss of heterozygosity (LOH, also referred to as
uniparental disomy) were identiﬁed, ranging in size from 3 to
29 Mbp on multiple chromosomes. CGH did not demonstrate any
large regions of copy neutral LOH in 10 patients with acquired
severe AA with normal cytogenetics, nor in 35 healthy controls.
Emerging data show that SNP arrays can detect abundant copy
neutral LOH amongst select hematologic malignancies and are
associated with the duplication of oncogenic mutations [7]. Addi-
tion of SNP arrays to standard cytogenetics increases the ability to
identify a clonal marker from 50% to 80% [6]. When we compared
locations of LOH in our patient with reported genes involved in
evolution of mutations in AML we found several important over-
laps (Table 1). These results suggest SNP based CGH arrays may be
useful in distinguishing hypocellular AML from AA.
3. Discussion
To our knowledge, we report for the ﬁrst time t(8;21) acute
myeloid leukemia presenting as severe aplastic anemia. t(8;21)
(q22;q22) is present in 5–10% of all AMLs, and includes variety of
subtypes with varying pathology, and clinical presentations, ran-
ging from circulating blast in peripheral blood to absent blasts
forms [5,8,9]. However, it is important to note that t(8;21) is not
associated with bone marrow failure disorders. Our patient devel-
oped frank leukemia eight months following diagnosis; however,
one may have predicted leukemia at the time of diagnosis of AA.
While initial bone marrow biopsy lacked any cytogenetic abnorm-
alities in 20 analyzed metaphases, repeat bone marrow biopsy
eight days later demonstrated t(8;21) in 3 out of 20 metaphases. In
this regard, analyzing 20 metaphases was not sufﬁcient. Further
complementary molecular tests, such as CGH, would likely provide
a more robust diagnosis of hematopoietic diseases.
Cytopenias are common in AML for unclear reasons. One
accepted mechanism is physical replacement of normal hematopoi-
etic stem cells (HSC) by myeloblasts, although blood counts may be
affected in the absence of marrow morphology showing abundant
blasts. Recently, Miraki-Moud et al. reported that leukemic cells
inhibited hematopoiesis by producing cytokines that suppress
differentiation of normal HSC and possibly reducing cycling of
HSC [10]. Indeed, our patient showed severe bone marrow failure
in the absence of myeloblasts. More sensitive assessment of
chromosome aberrations likely will reveal similar cases.
Fig. 1. (A) Bone marrow aspirate was analyzed in co-hybridization experiment of
RUNX1T1 (ETO; 8q22) and RUNX1 (AML1; 21q22.1). (B) HþE staining of bone
marrow at 200 magniﬁcation. (C) Representative IHC demonstrating cluster of
CD34þ cells.
Table 1
Association of LOH detected in patient and reported gens involved in evolution of
mutations in AML.
Chromosome LOH Genes associated with clonal evolution
2 (q24.2) TTN
3 (p21.2) FOXP1
7 (q34) MLL3, CUL1, EZH2
12 (q23.2) PTPN11
16 (p11.2) TP53TG3b, TP53TG3
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